Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Retained Earnings (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Retained Earnings for 6 consecutive years, with $30000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 74.79% to $30000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $30000.0, a 74.79% decrease, with the full-year FY2025 number at $30000.0, down 74.79% from a year prior.
  • Retained Earnings was $30000.0 for Q4 2025 at Lexicon Pharmaceuticals, up from -$2.0 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $119000.0 in Q4 2024 to a low of -$2.0 billion in Q3 2025.
  • A 3-year average of -$958.3 million and a median of -$883.5 million in 2023 define the central range for Retained Earnings.
  • Biggest YoY gain for Retained Earnings was 100.01% in 2024; the steepest drop was 1710940.71% in 2024.
  • Lexicon Pharmaceuticals' Retained Earnings stood at -$1.8 billion in 2023, then surged by 100.01% to $119000.0 in 2024, then crashed by 74.79% to $30000.0 in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Retained Earnings are $30000.0 (Q4 2025), -$2.0 billion (Q3 2025), and -$2.0 billion (Q2 2025).